Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 13/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 12/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16241938 | 0.93 | NOS1 (0.34) | FEN1ALOX5APAKR1B1HSD17B1 | |
| SCHEMBL7078300 | 0.84 | NOS1 (0.38) | FEN1ALOX5AP | |
| SCHEMBL218814 | 0.76 | NOS3 (0.40) | FEN1ALOX5AP | |
| SCHEMBL6583707 | 0.75 | FEN1 (0.43) | FEN1ALOX5AP | |
| SCHEMBL219308 | 0.75 | NOS1 (0.55) | GABRA1GABRB2 | |
| SCHEMBL419243 | 0.74 | MEN1 (0.39) | FEN1ALOX5AP | |
| SCHEMBL8096636 | 0.73 | GABRA1 (0.59) | AKR1B1GABRA1GABRB2 | |
| SCHEMBL6582620 | 0.73 | FEN1 (0.42) | FEN1ALOX5AP | |
| SCHEMBL6583994 | 0.70 | NOS3 (0.41) | FEN1ALOX5AP | |
| SCHEMBL28743148 | 0.70 | IKBKB (0.40) | FEN1ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030045449-A1 | Pharmaceutical combinations for the treatment of neurodegenerative diseases | PFIZER, INC. | 2003-03-06 | — | — | US | claimed |
| US-20030162765-A1 | Use in treatment and prevention of central nervous system and other disorders | PFIZER INC. | 2003-08-28 | — | — | US | disclosed |
| US-20010007873-A1 | Compounds such as 4-(6-amino-pyridin-2-yl)-3-methoxyphenol as nitric oxide synthase inhibitors used to treat central nervous system disorders, inflammatory disorders, septic shock, etc... | PFIZER INC. | 2001-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045449-A1 | Pharmaceutical combinations for the treatment of neurodegenerative diseases | GRIN3A, GRIN1, CHRNA10 | FEN1 3241/4885ALOX5AP 1670/4885AKR1B1 988/4885 |
| US-20010007873-A1 | Compounds such as 4-(6-amino-pyridin-2-yl)-3-methoxyphenol as nitric oxide synthase inhibitors used to treat central nervous system disorders, inflammatory disorders, septic shock, etc... | NOS1, PTGS1, NOS2 | FEN1 3816/4885ALOX5AP 251/4885AKR1B1 303/4885 |
| US-20030162765-A1 | Use in treatment and prevention of central nervous system and other disorders | GRIN2C, GRIN2A, CNR2 | FEN1 4809/4885ALOX5AP 1604/4885AKR1B1 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.